Auxilium Pharma (AUXL) Tops Q3 EPS by 17c

Auxilium Pharma (NASDAQ: AUXL) reported Q3 EPS of $0.27, $0.17 better than the analyst estimate of $0.10. Revenue for the quarter came in at $109.6 million versus the consensus estimate of $101.02 million.

"We are very pleased with the continued momentum and strong performance of the core growth products in our portfolio this quarter, especially the XIAFLEX franchise, which more than doubled in revenues over the same period in 2013. Additionally, STENDRA traction continues as the product is now the first and only erectile dysfunction treatment approved to be taken approximately 15 minutes before sexual activity," said Adrian Adams, Chief Executive Officer and President of Auxilium. "Given our recent announcement of the proposed acquisition of Auxilium by Endo International plc, we believe there is now an even greater opportunity to fully realize our current and future products' potential and drive significant shareholder value."

For earnings history and earnings-related data on Auxilium Pharma (AUXL) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Intuitive Surgical (ISRG) PT Raised to $435 at Piper Sandler
• Comerica (CMA) PT Raised to $54 at Piper Sandler